Latest Disease-modifying antirheumatic drug Stories

2008-10-09 18:00:37

Biogen Idec (NASDAQ: BIIB) announced today that its Phase II trial of baminercept (BG9924, LT(beta)R-Ig) in rheumatoid arthritis (RA) patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug (DMARD) did not meet its primary endpoint.

2008-09-18 12:00:11

NUTLEY, N.J., Sept. 18 /PRNewswire/ -- Roche today announced that the U.S.

2008-08-06 09:00:11

Hollis-Eden Pharmaceuticals has started a Phase I/II open label dose ranging clinical trial with its investigational oral drug candidate Triolex in patients diagnosed with rheumatoid arthritis and receiving a stable dose of methotrexate, the current standard of care in rheumatoid arthritis.

2008-07-31 12:00:22

Roche has announced that the arthritis advisory committee of the FDA has recommended approval of Actemra, a novel interleukin-6 receptor-inhibiting monoclonal antibody, for reducing the signs and symptoms in adults with moderate to severe rheumatoid arthritis.

2008-07-29 15:00:28

NUTLEY, N.J., July 29 /PRNewswire/ -- Roche today announced that the Arthritis Advisory Committee of the U.S.

2008-07-01 03:00:09

The European marketing authorisation application for Cimzia(R) has been filed. Subject to approval, Cimzia(R) will be the first and only PEGylated, Fc-Free anti-TNF (Tumour Necrosis Factor alpha) biologic therapy.

2008-06-25 09:02:11

Lux Biosciences today announced the completion of enrollment for the landmark LUMINATE (Luveniq Uveitis Multicenter Investigation of a New Approach to TrEatment) pivotal clinical trial program, which is investigating the use of LUVENIQ(TM) (voclosporin; previously designated LX211) as a corticosteroid-sparing agent for the treatment of patients with non-infectious uveitis.

2006-08-31 11:20:00

In patients with rheumatoid arthritis, use of disease-modifying antirheumatic drugs, or DMARDs, seems to lower the increased risk of cardiovascular disease associated with rheumatoid arthritis, research suggests.

2006-03-02 16:40:10

NEW YORK (Reuters Health) - Even if an initial course of methotrexate for the treatment of rheumatoid arthritis (RA) gives disappointing results, persistence may pay off. A second course may be more successful, researchers report.

Word of the Day
  • A serpent whose bite was fabled to produce intense thirst.
The word 'dipsas' comes from a Greek word meaning 'thirst'.